SLC5A2 and chronic kidney disease: Instead, reductions in cardiovascular disease and chronic kidney disease are now, through new and effective treatment options, priority treatment objectives.1 Two classes of drugs, sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, provide cardiovascular and kidney benefits, particularly in patients with established cardiovascular or kidney disease,2 with trustworthy guidelines providing recommendations stratified by baseline risks.2, 3